News
Hikma provides update on status of ANDA for generic Advair Diskus®
News
Hikma delivers strong first half performance and raises full year guidance
Update
Hikma update regarding COVID-19
Our H1 2020 results
Watch this short video summary of the highlights of our interim results.
Case study
Our support and impact for the Healthy Kitchen Project
Case study
Our support and impact; improving patient’s access to ritonavir
Insight
Two ways to minimise the impact of COVID-19 on vulnerable communities
Sustainability news
Hikma improves performance in FTSE4Good Index
Find out more
Who we are. We make high quality medicines and make them accessible to the people that need them.
Corporate social responsibility
Hikma launches employee matching donation campaign to support local US food banks and pantries
Find out more
Our commitment to sustainability
Find out more
We develop, manufacture and market nearly 700 quality branded and non-branded generic medicines worldwide.